Tim Opler, Flame Biosciences co-CEO
January 17, 2023 10:23 AM EST
Financing
Startups
Deals

Leap Ther­a­peu­tics jumps in­to grow­ing Claudin18.2 field by buy­ing Flame Bio­sciences

Kyle LaHucik

Senior Reporter

Flame Bio­sciences gave up on its IL-1ß in­hibitor last fall af­ter No­var­tis’ as­set in the class failed mul­ti­ple stud­ies. To save it­self, the biotech is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times